There are numerous differences in cardiovascular disease (CVD) between men and women. Women have a higher prevalence of coronary microvascular dysfunction, heart failure with preserved ejection fraction, Tako-Tsubo syndrome (also known as stress-induced cardiomyopathy), and post–myocardial infarction depression than men. Women also have a greater sensitivity to QT-prolonging medications and higher heart failure mortality with digoxin than men.1,2 A mounting literature further documents important sex differences in pharmacology, including response to β-blockers and angiotensin converting enzyme inhibitors.3
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Bairey Merz CN, Regitz-Zagrosek V. The Case for Sex- and Gender-Specific Medicine. JAMA Intern Med. 2014;174(8):1348–1349. doi:10.1001/jamainternmed.2014.320
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: